Bend Research, Inc.

Pfizer Corporation

Other

Pfizer Products Inc.

William John Curatolo

James A S Nightingale

Dwayne Thomas Friesen

Ravi Mysore Shanker

Douglas Alan Lorenz

Scott Max Herbig

Walter Christian Babcock

Roger B Ruggeri

Michael Jon Gumkowski

Hylar Lewis Friedman

Avinash G Thombre

Marshall David Crew

Leah Elizabeth Appel

James William West

Warren Kenyon Miller

Daniel Tod Smithey

Julian B Lo

Rodney James Ketner

Richard W Korsmeyer

Ronald Arthur Beyerinck

Jeelin Lo

Steven R LeMott

Mary T Am Ende

George H Foulds

Mark B Chidlaw

Kelly L Smith

James Blair West

John R Cardinal

Kenneth C Waterman

Ravi Mysore Shankar

Michael B Fergione

Michael C Roy

Charles D Ebert

Danni Supplee

Steven C Sutton

Leah A Appel

James Alan Schriver Nightingale

Roger Benjamin Ruggeri

A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.

Pharmaceutical compositions providing enhanced drug concentrations

A controlled release dosage form has a coated core with the core comprising a drug-containing composition and a water-swellable composition, each occupying separate regions within the core. The drug-containing composition comprises a low-solubility drug and a drug-entraining agent. The coating around the core is water-permeable, water-insoluble and has at least one delivery port therethrough. A variety of formulations having specific drug release profiles are disclosed.

Hydrogel-driven drug dosage form

A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.

Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers

Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or bioavailability in a use environment.

Solid pharmaceutical dispersions with enhanced bioavailability

A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.

Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors

Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or biavailability in a use environment.

Growing community of inventors

Niantic, CT, United States of America

William John Curatolo